Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double Blind, Placebo Controlled, Multicenter, 12 Weeks Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease

Next Previous
X
Search
Trial Profile

Randomized, Double Blind, Placebo Controlled, Multicenter, 12 Weeks Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nizubaglustat (Primary)
  • Indications GM2 gangliosidoses; Niemann-Pick disease type C; Sandhoff disease; Tay-Sachs disease
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms RAINBOW
  • Sponsors Azafaros

    • Most Recent Events

    • 19 Nov 2024 According to an Azafaros media release, the company will deliver a poster presentation on 6 Feb 2025 at the WORLDSymposium™ 2025, showing an analysis compares data from the RAINBOW and PRONTO studies, illustrating the role of natural history studies in guiding drug development.
    • 19 Nov 2024 According to an Azafaros media release, the company will host a satellite symposium on February 4, 2025 at 12:15, which will provide insights into the results from the RAINBOW study.
    • 19 Nov 2024 According to an Azafaros media release, an oral presentation on 6 Feb 2025, will highlight the results of this study at the upcoming WORLDSymposium™ 2025, the pre-eminent conference on lysosomal diseases, taking place from February 3 to 7 in San Diego, California.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top